Clinical Trials
Below are current clinical trials.
203 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
This study will be a retrospective and prospective analysis of patients with Post-COVID-19 symptoms that persist for greater than 28 days that are seen in the PCoCC (Post COVID Care Clinic), CARP, Pulmonary for post COVID clinic, Neurology, or approval by the MAGPIES research group.
Data for the registry will be aggregated from the EHR and by questionnaires. This data can be used to better guide strategic and tactical decisions as clinicians and healthcare managers respond to the rapidly evolving Post-COVID-19 patients.
The biobank will be optional for the participant and is designed to prospectively collect research biospecimens from Post-COVID-19 with symptoms that persist for greater than 28 days.
-
Scottsdale/Phoenix, Ariz.
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection.
All subjects will have additional PK and Immunogenicity blood samples collected.
-
Rochester, Minn.
The objective is to obtain and report outcome data for adult subjects who received systemic antifungal therapy (AFT) for the treatment of invasive mucormycosis (IM) or invasive aspergillosis (IA) caused by a non-fumigatus species.
-
Rochester, Minn.
The objective of this study is to evaluate the impact of the Alere™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.
-
Rochester, Minn.
The purpose of this study is to assess short and long term outcomes and factors related to poor prognosis in patients with neuroinvasive West Nile disease
-
Rochester, Minn.
The purpose of this study is to test whether metagenomic shotgun sequencing can identify pathogens causing cardiovascular infections such as infective endocarditis or myocarditis.
-
Rochester, Minn.
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
-
Jacksonville, Fla.
The purpose of this study, is to open expanded access at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Patients who have an aggressive, recurring hepatitis C infection following liver transplant, will be given sofosbuvir combined with ribavirin, and pegylated interferon may or may not be added at the discretion of the investigator.
-
Jacksonville, Fla.
The purpose of this study is to evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with chronic genotype 1 or 4 hepatitis C virus (HCV) infection. Participants will be randomized to receive 12 or 24 weeks of dosing with the LDV/SOF FDC tablet+ribavirin (RBV).
-
Scottsdale/Phoenix, Ariz.
This study will evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV upper respiratory tract infection (URTI), the effect of presatovir on development of lower respiratory tract complication, being free of any supplemental oxygen progression to respiratory failure, and pharmacokinetics (PK), safety, and tolerability of presatovir.